Why ClearPoint Neuro, Inc.’s (CLPT) Stock Is Up 7.34%
As of Thursday, October 29, ClearPoint Neuro, Inc.’s CLPT share price has surged by 7.34%, which has investors questioning if this is right time to sell.Rosalio Madrigal
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
Michael Rose
Jenna Brashear
| Share Statistics | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $342.0 | $383.9 | 34% |
|
| Shares Out (Mil) | 30.2 | 40.6 | 37% |
|
| Institutional Ownership | 87.9% | 83.3% | 56% |
|
| Float (Mil) | 26.3 | 35.1 | 33% |
|
| Beta | 1.29 | 0.90 | 75% |
|
| Avg Daily Volume (000s) | 642 | 323 | 63% |
|
| Price Change (52-week) |
(55.8%) | 62.8% | 18% |
|
| Growth | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 23.7% | 11.8% | 85% |
|
| Net Income (5yr) | (30.3%) | (5.6%) | 13% |
|
| EPS (5yr) | (16.1%) | 10.6% | 17 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 0.9% | (15.6%) | 65% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 2 | |
| Current EPS | ($0.230) | ($1.170) | ($1.100) | |
| Month Ago EPS | ($0.295) | ($1.305) | ($1.195) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 3 | |
| Three Months Ago EPS | ($0.243) | ($1.113) | ($0.940) | |
| Year/Year Chg | (38.8%) | 29.7% | (4.7%) | |
| Financials | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $42 | $141 | 19% |
|
| Net Income (TTM) (Mil) | ($35) | ($10) | 19% |
|
| EPS (TTM) | ($1.182) | ($0.400) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($30) | ($2) | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($11) | $1 | 30% |
|
| Long-Term Debt (Q1) (Mil) | $64 | $25 | 41% |
|
| Enterprise Value (Q1) (Mil) | $570 | $381 | 35% |
|
| Valuation | CLPT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 30.49 | 2.46 | 97% |
|
| P/E | na | 28.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.4 | na |
|
| Ratios | CLPT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.4% | 59.3% | 74% |
|
| Net Margin | (79.4%) | (6.9%) | 9% |
|
| ROA | (46.2%) | (12.1%) | 12% |
|
| ROE | (226.5%) | (10.3%) | 4% |
|
| Liabilities to Assets | 87.6% | 47.2% | 82% |
|
| F-Score | 2 | 4 | 7% |
|
ClearPoint Neuro, Inc. did not pass any screens on 10/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors